Browsing by Author Kalmeijer, R

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 7 of 7
TitleAuthor(s)Issue Date
 
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
Journal:Journal of Hepatology
Yuen, MFLocarnini SLim, THStrasser, SISievert WCheng, WThompson, AJGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KLai, CLGish, RGGane, E
14-Oct-2022
 
Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2019
 
Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study. Poster Presentation (SAT422)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Yuen, RMFAsselah, TJacobson, IMBrunetto, MJanssen, HTakehara, THou, JLKakuda8, TLambrecht, TKalmeijer, RGuinard-Azadian, CMayer, CJerzorwski, JVerbinnen, TLenz, OShukla, UBiermer, M
2022
 
First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA)
Proceeding/Conference:Hepatology
Yuen, RMFLocarnini, SGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GJackson, KFerrari, CLai, CLLiu, SHKMak, LYWong, DKHTo, WPKo, KLGish, RG
2019
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2021
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B (CHB) shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International
Gane, ELocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AJGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont, MLenz, ORidder, FDCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RYuen, RMF
2022
 
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2020
Showing results 1 to 7 of 7